Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Clinical trial NCT06652685 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06652685
- Sponsor
- Ruijin Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-30
- Primary completion
- 2026-10-31
- Enrollment
- 218
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.